![]() |
![]() |
Legal status
Patent expired
(51) | INT.CL. | A61K 39/12 | (2006.01) |
(11) | Number of the document | 1758609 |
(13) | Kind of document | T |
(96) | European patent application number | 05757953.4 |
Date of filing the European patent application | 2005-06-14 | |
(97) | Date of publication of the European application | 2007-03-07 |
(45) | Date of publication and mention of the grant of the patent | 2012-10-03 |
(46) | Date of publication of the claims translation | 2012-12-27 |
(86) | Number | PCT/EP2005/006461 |
Date | 2005-06-14 |
(87) | Number | WO 2005/123125 |
Date | 2005-12-29 |
(30) | Number | Date | Country code |
0413510 | 2004-06-16 | GB | |
114301 | 2005-04-26 | US |
(72) |
DEBRUS, Serge, BE
MARTIN, Marie-Therese, BE
STEPHEN, Robert John, GB
STEPHENNE, Jean, BE
WETTENDORFF, Martine, Anne, Cécile, BE
|
(73) |
GlaxoSmithKline Biologicals SA,
Rue de l`Institut 89, 1330 Rixensart,
BE
|
(74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
(54) | Vakcina prieš HPV16 ir HPV18 ir mažiausiai vieną kitą HVP tipą, parinktą iš HVP 31, 45 arba 52 |
VACCINE AGAINST HPV16 AND HPV18 AND AT LEAST ANOTHER HPV TYPE SELECTED FROM HPV 31, 45 OR 52 |
Payment date | Validity (years) | Amount | |
2024-05-21 | 347.00 EUR |